Sandu Pharmaceuticals Limited informed the BSE that the name of its Non-Executive Independent Director, Dr Neeti Madan Kapre, has been changed to Dr Neeti Gupta. The modification is a result of her marriage.

The company stated that the change in name has been duly supported by relevant documentary evidence and taken on record. This intimation was filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Disclosure Details

The company confirmed that there is no change in the designation, directorship, or Director Identification Number (DIN) of the director. The update pertains solely to the change in her surname.

The filing was signed by Pratika Mhambray, Company Secretary and Compliance Officer, on October 9, 2026. The company remains compliant with all listing obligations regarding key managerial personnel disclosures.

Sandu Pharmaceuticals has confirmed that all eight resolutions at its 41st Annual General Meeting held on September 11, 2026, were passed with overwhelming shareholder support. The approvals include significant board changes, notably the redesignation of Shri Balram Viswanathan as Chairman and Managing Director and the appointment of Dr Neeti Madan Kapre as a Non-Executive Independent Director.

The meeting, conducted via video conferencing, saw participation from 54 shareholders representing promoter and public categories. Remote e-voting was facilitated from September 8 to September 10, 2026, while electronic voting during the meeting was handled via NSDL. CS Swapnil Dixit, the appointed scrutinizer, confirmed that the e-voting process was conducted fairly and transparently in compliance with SEBI LODR Regulations and MCA guidelines.

Voting Participation and Results

The total number of shareholders on the record date (September 4 to September 11, 2026) stood at 10,523. Of the 96,60,990 shares eligible to vote, approximately 44.49% participated in the voting process across various resolutions.

Promoter and promoter group shareholders held 36,50,548 shares, while public non-institutional shareholders held 60,09,942 shares. Public institutional holdings were minimal at 500 shares.

Key Resolutions Passed

All ordinary and special business items received overwhelming support, with approval rates consistently exceeding 99.99% for most agenda items. The key outcomes include:

• Financial Statements: Adoption of audited standalone financial statements for FY26 passed with 99.99% votes in favour.
• Dividend Declaration: The resolution to declare a dividend on equity shares for FY26 secured 99.99% approval.
• Auditor Appointment: M/s. Dave & Dave, Chartered Accountants, were appointed as Statutory Auditors for five years, passing with 99.99% support.
• Governance Changes: The redesignation of Shri Balram Viswanathan as Chairman and Managing Director passed as a special resolution with 99.99% votes in favour.
• Board Appointments: Smt. Jayshree Sandu was reappointed as a director retiring by rotation (99.99% approval), and Smt. Dr Neeti Madan Kapre was appointed as a Non-Executive Independent Director (99.99% approval).
• Related Party Transactions: Material related-party transactions with Sandu Brothers Private Limited were approved with 99.99% support.
• Cost Auditor: Ratification of the Cost Auditor’s remuneration passed with 99.99% approval.

Board Appointment Details

The new data provides specific terms and profiles for the key board appointments approved at the AGM:

Shri Balram Viswanathan, who holds a B.Com., FCA, and CPA (USA), brings over 30 years of experience in financial services, including audit, taxation, M&A advisory, and risk management. He is not related to any other Director or Key Managerial Personnel of the company.

Dr Neeti Madan Kapre is an MBBS Gold Medallist and MS (ENT) specialist from K.E.M. Hospital, Mumbai. She has served as a Clinical Research Fellow and completed fellowships at Memorial Sloan Kettering Cancer Centre, New York. She is a founder member of the Indian Society of Thyroid Surgeons and the Vidarbha Society of Head and Neck Oncology.

Both appointments were made effective from July 11, 2026, preceding the AGM date where they received formal shareholder ratification.